CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Hangzhou Diagens Biotechnology Co., Ltd./ADR

HGZDY
N/A

Next catalyst

PDUFAOctober 2027

Picankibart

Rheumatoid Arthritis

Get an email about HGZDY's next catalysts

Track Hangzhou Diagens Biotechnology Co., Ltd./ADR (HGZDY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 0 past

PDUFANext

FDA PDUFA Date Zemprocitinib

October 2027~Picankibart

For Rheumatoid Arthritis. NDA accepted. AI-extracted from: Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zempr

Source

Market Overview

Stock performance and key metrics

NASDAQBiotechnologyπŸ‡ΊπŸ‡ΈNorth AmericaHANGZHOU
Drug Pipeline

Frequently asked questions

What is in Hangzhou Diagens Biotechnology Co., Ltd./ADR's drug pipeline?β†’

CatalystAlert tracks 2 drug candidates in Hangzhou Diagens Biotechnology Co., Ltd./ADR's (HGZDY) pipeline across Phase 3. Its lead program is Picankibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Hangzhou Diagens Biotechnology Co., Ltd./ADR's next FDA catalyst?β†’

Hangzhou Diagens Biotechnology Co., Ltd./ADR's (HGZDY) next tracked catalyst is a PDUFA date expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track HGZDY biotech catalysts?β†’

Add HGZDY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hangzhou Diagens Biotechnology Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply